Skip to main content
. Author manuscript; available in PMC: 2016 May 10.
Published in final edited form as: Cancer Gene Ther. 2013 Jul 5;20(8):437–444. doi: 10.1038/cgt.2013.38

Figure 5.

Figure 5

Induction of Caspase-8 and -9 by treatment with RAMBO, cilengitide, and RAMBO and cilengitide combined in vitro. A: Caspase-8 activity assay. U87ΔEGFR glioma cells were treated with cilengitide (10 µM), with RAMBO (MOI 0.1), and with RAMBO and cilengitide combined (same as above). At 16 h after infection with RAMBO and 13 h after adding cilengitide or PBS, caspase activity was evaluated in the cells using a FLICE/Caspase-8 Colorimetric Assay Kit. There was a significant increase in caspase-8 activity in glioma cells treated with cilengitide compared to those of control. The symbol (*) show a significant increase in caspase-8 activity. B: Assay of caspase-9 activity. U87ΔEGFR glioma cells were treated as mentioned, and evaluated using a Caspase-9 Colorimetric Assay Kit. There was a significant increase in caspase-9 activity in glioma cells treated with RAMBO compared to those of (A: *: P = 0.043, B: *: P = 0.043, respectively).